# Performance in Initiating Clinical Trials Q2 2016-2017
## 70 day benchmark, valid application to first participant recruited
## NHS Permission Studies only

| Research Ethics Committee Number | IRAS Number | Name of Trial | Receipt of Valid Research Application | Date of First Patient Recruited | Benchmark Met | Comments |
|---|---|---|---|---|---|---|
| 15/SC/0502 | 184517 | The Nightmare Intervention Study: a pilot randomised controlled trial of a brief cognitive behavioral therapy for nightmares for patients with persecutory delusions | 23/11/2015 | 01/02/2016 | Yes | |
| 15/SS/0032 | 165287 | STARBEAM Ext: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease | 09/02/2016 | 01/03/2016 | Yes | |
| 14/LO/2071 | 160786 | Preventing enduring behavioural problems in young children through early psychological intervention: Healthy Start, Happy Start | 08/01/2016 | 12/02/2016 | Yes | |
| 15/SC/0508 | 186095 | Psychological support for fears about other people: A comparison of the Feeling Safe Programme to befriending | 22/01/2016 | 08/02/2016 | Yes | |
| 15/YH/0051 | 172273 | A Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR+) : a definitive randomised evaluation of a bespoke smoking cessation service | 29/03/2016 | 17/05/2016 | Yes | |
| 15/SC/0432 | 181387 | A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatment-resistant Depression - TRANSFORM | 28/03/2016 | | No | The sponsor recognised study is difficult to recruit to for all sites and has extended recruitment and introduced a new recruitment tool. |
| 15/SC/0434 | 181955 | An open-label, long-term, safety and efficacy study of intranasal Esketamine in Treatment-resistant Depression in Adults SUSTAIN-2 | 28/03/2016 | 17/06/2016 | No | This study has been difficult to recruit to for all sites. Sponsor has initiated a new recruitment tool. |
| 15/NE/0269 | 188082 | A Parallel-Group, Double Blind Long Term Safety Trial of MK-8931 in Subjects with Alzheimer’s Disease. (Protocol No. MK-8931-017-12) - EPOCH Ext | 05/04/2016 | 04/07/2016 | No | A sponsor error meant that the study site was not able to start recruitment despite being ready. |